SHENYANG, China, March 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (NASDAQ:SSRX) ('3SBio' or the 'Company'), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Dr. David Chen to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Dr. Chen most recently held the position of Vice President of Business Development at 3SBio.
Since joining 3SBio in June 2007, Dr. Chen has been responsible for developing long-range growth strategies and pursuing strategic business opportunities and external alliances with biotechnology and pharmaceutical companies in major markets worldwide. In addition to his existing responsibilities, Dr. Chen will assume oversight of commercial operations including commercial strategy, medical and regulatory, government affairs, and export. He will be based in Beijing, China.
Dr. Jing Lou, CEO of 3SBio, commented, 'I am very pleased to announce the promotion of David Chen to the position of Chief Operating Officer. Since assuming the role of VP of Business Development, David has quickly demonstrated his leadership skills and has played a critical role in planning and executing our future growth strategies and partnering initiatives, helping to establish relationships with a number of potential partners around the world. His in-depth understanding of the Chinese pharmaceutical market place combined with his significant operating experience with multinational pharmaceutical companies in the US make him the ideal candidate to assume this newly created position. I look forward to working together with David as we help drive the next phase of 3SBio's growth.' Prior to joining 3SBio, Dr. Chen, 42, held various managerial positions in the US pharmaceutical industry, including business development, sales and marketing, market research, new product development and R&D portfolio management both with Eli Lilly and GlaxoSmithKline. Prior to his experience in the US, Dr. Chen was a practicing orthopedic surgeon at Shanghai Medical University from 1989 to 1992. He received a medical degree from the First Military Medical University in Guangzhou, China, and earned a Masters Degree in Business Administration from the Darden School of Business at the University of Virginia.
About 3SBio Inc.
3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com/ .
For more information, please contact: Investor Contact:
Kevin Teo, CFO
3SBio Inc. Tel: +86-24-2581-1820
Email: Investor Relations(HK):
Ruby Yim
Taylor Rafferty
Tel: +852-3196-3712
Email: Investor Relations(US):
Mahmoud Siddig
Taylor Rafferty
Tel: +1-212-889-4350
Email: Media Contact:
John Dooley
Taylor Rafferty
Tel: +1-212-889-4350
Email: DATASOURCE: 3SBio Inc.
CONTACT: Kevin Teo, CFO 3SBio Inc., +86-24-2581-1820 or ; HK Investor Relations: Ruby Yim +852-3196-3712; US Investor Relations: Mahmoud Siddig +1-212-889-4350; Media Contact: John Dooley +1-212-889-4350 ; all three for Taylor Rafferty at Web Site: http://www.3sbio.com/
|